Autoimmune and inflammatory diseases
3 European H2020 organizations list this as part of their work — 1 as their primary capability.
Most active in this area
- NOVARTIS PHARMA AG
Global pharmaceutical company contributing clinical data, drug safety expertise, and translational medicine capabilities to large-scale European health research consortia.
“Focused involvement in NECESSITY (Sjögren's syndrome), IMI-PainCare, and recent keyword clusters around atopic dermatitis and psoriasis.”
CH57 projects - UNIVERSITATSKLINIKUM ERLANGEN
German university hospital strong in autoimmune disease, bone biology, cancer research, and increasingly in digital health and AI-driven clinical imaging.
“Core focus spanning RTCure (rheumatoid arthritis tolerance), BARRIER BREAK (skin-to-joint inflammation), H I C I (CNS autoimmune inflammation), NeutroCure (neutrophil-driven autoimmunity), HIPPOCRATES (psoriatic arthritis), and REDOXIT (ROS in chronic disease).”
PrimaryDE27 projects - INNOVATION ACTA SRL
Italian SME providing clinical trial design and regulatory support for advanced therapies, immunomodulation, and multi-center European health studies.
“NECESSITY addressed Sjögren's syndrome with multi-arm clinical trial design; RESHAPE targeted inflammation through next-generation regulatory T cells.”
SMEIT9 projects